Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
- Sponsor
- American University of Beirut Medical Center
- Study ID
- NCT00403988
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Oxaliplatin — DRUG
- vinorelbine — DRUG
Study Details
Study Objective : To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer
Key Dates
- Start date
- Jun 30, 2004
- Status verified
- Aug 2008
- Completion
- Dec 31, 2007
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
overall response rate [ Time Frame: During the Study Conduct ]
Related Studies
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer CellsRecruiting · Washington University School of Medicine · St Louis, Missouri
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScorePHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- A Registry Study of Breast Microseed TreatmentRecruiting · Concure Oncology-Breast Microseed Inc. · Pittsburgh, Pennsylvania